

-JFW

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Applicant:


AYALON-SOFFER Michal et al

Serial No.: 10/764,833

Filed: January 27, 2004

For: Novel Polynucleotides Encoding Soluble Polypeptides ...

Examiner:



§
§
§
§
§
§
§
§
§
§
§

Group Art Unit: 1631

Attorney
Docket: 27256

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Sir:

Enclosed is a PTO Form 1449 which lists citations which may be material to the patentability and examination of the above identified application. Also enclosed are copies of the references cited. These are submitted in compliance with the duty of disclosure defined in 37 CFR 1.56. The Examiner is requested to make these citations of official record in this application.

This application is a CIP of 10/426,002 filed 04/30/03 and is a CIP of 10/242,799 filed 09/13/2002. Applicant requests that MPEP 609 be complied with and the examiner consider information which has been considered by the Office in a parent application when examining (A) a continuation application, (B) a divisional application, or (C) a continuation-in-part application.

This Information Disclosure Statement under 37 CFR 1.56 is not to be construed as a representation that a search has been made, that additional matter which is material to the examination of this application does not exist, or that any or more of these citations constitutes prior art.

Respectfully submitted,


Sol Sheinbein

Registration No. 25,457

Dated: November 7, 2004

Approved for use through 06/30/2006. OMB 0651-0031

U.S. Patent and Trademark Office U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>				Application Number	10/764,833
				Filing Date	January 27, 2004
				First Named Inventor	AYALON-SOFFER Michal et al
				Group Art Unit	1631
				Examiner Name	
Sheet	1	Of	3	Attorney Docket Number	27256
OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS					
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.			T ²
		Naka et al, "The paradigm of IL-6: from basic science to medicine" Arthritis Res. 2002;4 Suppl 3:S233-42. Epub 2002 May 09. Review			
		Furge et al, "Met receptor tyrosine kinase: enhanced signaling through adapter proteins" Oncogene. 2000 Nov 20;19(49):5582-9.			
		Deonarain et al, "Interferon-alpha/beta-receptor interactions: a complex story unfolding", Curr Pharm Des. 2002;8(24):2131-7.			
		Blazar et al, "Ligation of 4-1BB (CDw137) regulates graft-versus-host disease, graft-versus-leukemia, and graft rejection in allogeneic bone marrow transplant recipients", J Immunol. 2001 Mar 1;166(5):3174-83.			
		Fry et al, "Interleukin-7: from bench to clinic", Blood. 2002 Jun 1;99(11):3892-904			
		Attasano et al, "Signal transduction by the TGF-beta superfamily", Science. 2002 May 31;296(5573):1646-7.			
		Kerr et al, "Small molecule alpha(v) integrin antagonists: novel anticancer agents", Expert Opin Investig Drugs. 2000 Jun;9(6):1271-9.			
		To et al, "The roles of hepatocyte growth factor/scatter factor and met receptor in human cancers (Review)", Oncol Rep. 1998 Sep-Oct;5(5):1013-24			
		Simpson et al, "Interleukin-6: structure-function relationships", Protein Sci. 1997 May;6(5):929-55.			
		Cosenza et al, "Comparative model building of interleukin-7 using interleukin-4 as a template: a structural hypothesis that displays atypical surface chemistry in helix D important for receptor activation", Protein Sci. 2000 May;9(5):916-26.			
		Comoglio et al, "Invasive growth: from development to metastasis", J Clin Invest. 2002 Apr;109(7):857			
		Brierley et al, "IFN-alpha/beta receptor interactions to biologic outcomes: understanding the circuitry", J Interferon Cytokine Res. 2002 Aug;22(8):835-45.			
		Aggarwal, BB, "Signalling pathways of the TNF superfamily: a double-edged sword", Nat Rev Immunol. 2003 Sep;3(9):745-56			
		Tucker, GC, "αv Integrin inhibitors and cancer therapy", Curr Opin Invest Drugs, 4(6):722-731,2003			
		Nelms et al, "The IL-4 receptor: signaling mechanisms and biologic functions", Annu Rev Immunol. 1999;17:701-38			
		Moor et al, "Interleukin-10 and the interleukin-10 receptor", Annu Rev Immunol. 2001;19:683-765.			
		Pan et al, "IL-4 receptor mutations", Curr Opin Immunol. 1999 Dec;11(6):615-20.			
		Seo et al, "Blocking 4-1BB/4-1BB ligand interactions prevents herpetic stromal keratitis", J Immunol. 2003 Jul 15;171(2):576-83.			
		Vinay et al, "Role of 4-1BB in immune responses", Semin Immunol. 1998 Dec;10(6):481-9.			

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹. Applicant's unique citation designation number (optional). ². Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. this collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS.

SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Complete if Known

Application Number	10/764,833
Filing Date	January 27, 2004
First Named Inventor	AYALON-SOFFER Michal et al
Group Art Unit	1631
Examiner Name	
Attorney Docket Number	27256

Sheet	2	Of	3
		Zhang et al "HGF/SF-met signaling in the control of branching morphogenesis and invasion", J Cell Biochem. 2003 Feb 1;88(2):408-17.	
		Walter, MR, "Structure of interleukin-10/interleukin-10R1 complex: a paradigm for class 2 cytokine activation", Immunol Res. 2002;26(1-3):303-8.	
		Gessner et al, "Biologic functions and signaling of the interleukin-4 receptor complexes", Immunobiology. 2000 Jan;201(3-4):285-307	
		Croft M, "Costimulation of T cells by OX40, 4-1BB, and CD27", Cytokine Growth Factor Rev. 2003 Jun-Aug;14(3-4):265-73	
		Hirano T, "Interleukin 6 and its receptor: ten years later", Int Rev Immunol. 1998;16(3-4):249-84.	
		Asadullah et al, "Interleukin-10 therapy--review of a new approach", Pharmacol Rev. 2003 Jun;55(2):241-69.	
		Meuller et al, "Structure, binding, and antagonists in the IL-4/IL-13 receptor system", Biochim Biophys Acta. 2002 Nov 11;1592(3):237-50.	
		VanderSpek et al, "Structure function analysis of interleukin 7: requirement for an aromatic ring at position 143 of helix D", Cytokine. 2002 Mar 7;17(5):227-33.	
		Kotenko SV, "The family of IL-10-related cytokines and their receptors: related, but to what extent?", Cytokine Growth Factor Rev. 2002 Jun;13(3):223-40	
		Wrana JL, "TGF-beta receptors and signalling mechanisms", Miner Electrolyte Metab. 1998;24(2-3):120-30	
		Kwon et al, "4-1BB: still in the midst of darkness", Mol Cells. 2000 Apr 30;10(2):119-26.	
		Miyazono K, "TGF-beta receptors and signal transduction", Int J Hematol. 1997 Feb;65(2):97-104.	
		Brattain et al, "The type II transforming growth factor-beta receptor as a tumor-suppressor gene", Curr Opin Oncol. 1996 Jan;8(1):49-53.	
		Bihl et al, "Identification of a novel IL-6 isoform binding to the endogenous IL-6 receptor", Am J Respir Cell Mol Biol. 2002 Jul;27(1):48-56.	
		Maulik et al, "Role of the hepatocyte growth factor receptor, c-Met, in oncogenesis and potential for therapeutic inhibition", Cytokine Growth Factor Rev. 2002 Feb;13(1):41-59.	
		Gorgun et al, "Altered biological activity associated with C-terminal modifications of IL-7", Cytokine. 2002 Oct 7;20(1):17-22.	
		Mark et al, "Expression and characterization of hepatocyte growth factor receptor-IgG fusion proteins. Effects of mutations in the potential proteolytic cleavage site on processing and ligand binding", J Biol Chem. 1992 Dec 25;267(36):26166-71.	
		Mould et al, "Molecular basis of ligand recognition by integrin alpha 5beta 1. I. Specificity of ligand binding is determined by amino acid sequences in the second and third NH2-terminal repeats of the alpha subunit", J Biol Chem. 2000 Jul 7;275(27):20324-36.	
		Moustakas et al, "Smad regulation in TGF-beta signal transduction", J Cell Sci. 2001 Dec;114(Pt 24):4359-69	


*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹. Applicant's unique citation designation number (optional). ². Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS.

SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.



Supplement for form 1443-A/FTC

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Complete if Known	
Application Number	10/164,855
Filing Date	January 27, 2004
First Named Inventor	AYALON-SOFFER Michal et al
Group Art Unit	1631
Examiner Name	
Attorney Docket Number	27256

[illegible]

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹. Applicant's unique citation designation number (optional). ². Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS.**

SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.